Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression analysis of epidermal barrier functions associated genes in HaCaT cell treated by All-trans retinoic acid and Nicotinamide

ABSTRACT: Expression analysis of epidermal barrier functions associated genes in HaCaT cell treated by All-trans retinoic acid and Nicotinamide

PROVIDER: PRJNA510952 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression analysis of epidermal barrier functions associated genes in HaCaT cell and mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:Expression analysis of epidermal barrier functions associated genes in HaCaT cell and mouse epidermis treated by All-trans retinoic acid and Nicotinamide

| PRJNA510955 | ENA

Expression analysis of epidermal barrier functions associated genes in mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:Expression analysis of epidermal barrier functions associated genes in mouse epidermis treated by All-trans retinoic acid and Nicotinamide

| PRJNA510954 | ENA

Expression analysis of epidermal barrier functions associated genes in HaCaT cell treated by All-trans retinoic acid and Nicotinamide

Project description:Investigation of molecular mechanisms of impaired skin barrier by ATRA

2018-12-21 | GSE124179 | GEO

Expression analysis of epidermal barrier functions associated genes in HaCaT cell and mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-12-21 | GSE124183 | GEO

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Project description:The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

| 70824 | ecrin-mdr-crc

RIME against PBX1 protein in P19.6 mouse embryonal carcinoma cells treated for 48 hours with all-trans retinoic acid

Project description:Identification of PBX1 interactors in P19.6 mouse embryonal carcinoma cells treated for 48 hours with all-trans retinoic acid.

2017-04-03 | PXD006158 | Pride

Human epidermal keratinocytes treated with retinoic acid or thyroid hormone

Project description:Targets of Retinoic Acid (RA) were identified in primary human epidermal keratinocytes grown in the presence or absence of all-trans retinoic acid for 1, 4, 24, 48 and 72 hours. Targets of Thyroid Hormone (T3) were identified in primary human epidermal keratinocytes grown in the presence or absence of the hormone; same controls as for RA.

2010-06-11 | GSE22298 | GEO

Gene expression changes in mouse neuroepithelial organoids in response to all-trans retinoic acid.

Project description:We describe the transcriptomic changes in neuroepithelial organoids in response to all-trans retinoic acid.

2022-10-01 | GSE214368 | GEO

Human epidermal keratinocytes treated with retinoic acid or thyroid hormone

2010-06-23 | E-GEOD-22298 | biostudies-arrayexpress

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

| PRJNA1061109 | ENA